Experts SpeakOut: CME Online - Conversations on Multiple Sclerosis:

This program examines the essential methods used in assessing treatment optimization in RRMS, including ongoing monitoring of patients, evaluation of indicators that reflect persistent disease activity, and recognition of suboptimal responses to therapy.

This program will examine the clinical and psychosocial challenges in the long-term care of MS, including issues related to extended use of disease-modifying therapies.

You are cordially invited to participate in the Experts SpeakOut TeleSessions program. Join your peers for an interactive, 1-hour accredited teleconference led by Dr. Randall Schapiro. To register or for more information, please call 800/372-4100 and mention the Experts SpeakOut program, or visit http://www.telesession.com/reg/538006W/538006.html

This program provides up-to-date information on the long-term use of immunomodulatory and immunosuppressive disease-modifying therapies currently approved for MS.

This program provides up-to-date information on the long-term use of immunomodulatory and immunosuppressive disease-modifying therapies currently approved for MS.

This program provides up-to-date information on the role of conventional and emerging magnetic resonance imaging techniques in the diagnosis and management of MS.

This program reviews the essentials of the diagnosis of multiple sclerosis (MS) and to provide a rational approach to using MS disease-modifying therapies (DMTs), including strategies for optimizing treatment.

This program provides the latest information on the side effects associated with the available disease-modifying therapies (DMTs) used to treat relapsing-remitting multiple sclerosis (RRMS) and to offer strategies for their management.

This program provides information on neutralizing antibodies (NAbs) and their effects on patients with MS including insights into factors affecting the formation of NAbs, a review of available assay techniques and their associated challenges, and a discussion of the clinical relevance of NAbs in specific MS treatments.

This program provides an overview of recent insights into the pathogenesis of MS and discusses possible new approaches and therapeutic targets to deal with this disabling disease. The modes of action of the available immunomodulating therapies for MS are reviewed, with an emphasis on their potential to synergistically combine anti-inflammatory, immunomodulatory, and potentially neuroprotective actions.

This program provides a comparative overview of the available immunomodulating therapies for MS, including a review of their mechanisms of action, a discussion of current MRI concepts of disease activity and destructive pathology as they relate to the effects of the immunomodulators, and a review of their long-term effects and safety.